Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET0111 in Advanced Solid Tumors
NCT05522309Phase 1Unknown
- Sponsor
- ETERN Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET0111 in solid tumor (advanced stage), sponsored by ETERN Therapeutics. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase 2 Dose at 2 years and 1 more. Status: unknown.
02
Drugs
ET0111
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05522309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522309.